NEW YORK (GenomeWeb News) – Sigma-Aldrich said Tuesday that it will distribute Stemgent’s lentiviral vector-based technologies to the stem cell research community through a global agreement.
The worldwide distribution agreement covers Stemgent’s lentivirus-based delivery systems for induced pluripotent stem cells.
It includes Stemgent’s viral vectors, Sigma-Aldrich’s lentivirus technology, and Dox Inducible expression from Heidelberg, Germany-based TET Systems.
Stemgent’s technologies are aimed at researchers who are reprogramming mouse and human cells into iPS cells, particularly for use in regenerative medicine and disease studies.
Stemgent’s reagents and tools include small molecules for pluripotency, self-renewal, differentiation, viral-delivered transcription factors, cell lines, cytokines, transfection reagents, and others.